Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - An economic evaluation based on the fracture intervention trial

Osteoporosis International

Volumn 18, Issue 8, 2007, Pages 1047-1061

  Strom O ^a   Borgstrom F ^a,b   Sen, S S ^c   Boonen, S ^d   Haentjens, P ^e   Johnell, O ^f   Kanis, J A ^g  

^a European Health Economics   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Alendronate; Bisphosphonates; Cost; Europe; Fracture; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; EUROPE; FEMALE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POPULATION RESEARCH; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MARKOV CHAINS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SPINAL FRACTURES;

EID: 34248642474     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0349-5     Document Type: Article

References (91)

1. Melton LJ 3rd (1993) Hip fractures: a worldwide problem today and tomorrow. Bone 14(Suppl 1):S1-S8
2. Black DM, FIT Research Group et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 85(11):4118-4124
3. Black DM, Fracture Intervention Trial Research Group et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348(9041):1535-1541
4. Cummings SR et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. Jama 280(24):2077-2082
5. Johnell O et al (2003) Cost-effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21(5):305-314
6. Borgström F et al (2003) Cost-effectiveness of alendronate for the treatment of postmenopausal women in the UK. submitted
7. Borgström F et al (2003) Cost-Effectiveness of alnedronate in the treatment of male osteoporosis. Bone. accepted
8. Jonsson L, Borgstrom F, Zethraeus N (2003) [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the fracture intervention trial]. Ugeskr Laeger 165(43):4112-4116
9. Rosner AJ et al (1998) Cost-effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 14(5):559-573
10. Christensen PM, Brixen K, Kristiansen IS (2003) Danish osteoporosis outcome model (DOOM)
11. Borgstrom F, Zethraeus N (2003) [Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective]. Lakartidningen 100(1-2):36-40
12. Stevenson M, Davis S (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. [cited 2007-01-03]; Available from: http://www.nice.org.uk/page.aspx?o=370643
13. Stock JL et al (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103(4):291-297
14. Greenspan SL et al (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137(11):875-883
15. Tonino RP, Phase III Osteoporosis Treatment Study Group et al (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85(9):3109-3115
16. Bone HG et al (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(12):1189-1199
17. Borgstrom F et al (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: Based on the results of the SOTI and TROPOS trials. Osteoporos Int 17(12):1781-1793
18. Federaal Ministerie van Sociale Zaken, Volksgezondheid en Leefmilieu. (Belgium)
19. Vestergaard P, Rejnmark L, Mosekilde L (2005) Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 16(2):134-141
20. Elffors I et al (1994) The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int 4(5):253-263
21. Lofthus CM et al (2001) Epidemiology of hip fractures in Oslo, Norway. Bone 29(5):413-418
22. Kanis JA et al (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11(8):669-674
23. Singer BR et al (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80(2):243-248
24. Brecht JG et al (2003) Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 23(4):93-105
25. Kanis JA et al (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11(2):120-127
26. Kanis JA et al (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15(11):862-871
27. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312(7041):1254-1259
28. Looker AC et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8(5):468-489
29. Klotzbuecher CM et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721-739
30. Kanis JA et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375-382
31. Felsenberg D et al (2002) Incidence of vertebral fracture in Europe: results from the European prospective osteoporosis study (EPOS). J Bone Miner Res 17(4):716-724
32. Report on osteoporosis in the European community-action for prevention. 1998, European Commission-Employment & Social Affairs
33. Zethraeus N (1998) Willingness to pay for hormone replacement therapy. Health Econ 7(1):31-38
34. Life tables, years 1999-2001. Institut National d'Édutes démographiques. 2004
35. Johannesson M (1996) Theory and methods of economic evaluation of health care. Dev Health Econ Public Policy 4:1-245
36. Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Med Care 38(6):583-637
37. Statistics Norway http://www.ssb.no/). 2004
38. Christensen PM et al (2005) Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 96(5):387-396
39. Statistics Sweden. Sweden's Statistical Databases. http://www.scb.se/eng/ databaser/ssd.asp
40. Interim Life Tables. 2002 [cited http://www.gad.gov.uk/policy_and_stats/ life_tables.htm
41. Oden A et al (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8(6):599-603
42. Kanis JA et al (2003) The components of excess mortality after hip fracture. Bone 32(5):468-473
43. Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105(6):443-446
44. Kanis J et al (2002) Excess mortality after vertebral fracture. WHO Collabortaing centre for metabolic bone diseases: Sheffield, UK
45. ISPOR, Pharmacoeconomic guidelines. 2005, http://www.ispor.org/ PEguidelines/index.asp
46. TIPOS DE INTERÉS, BANCO DE ESPAÑA/ESTADÍSTICAS COMPLEMENTARIAS. http://www.bde.es/, 2005
47. Zethraeus N et al (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68(1):13-17
48. Zethraeus N et al (2002) Costs and quality of life associated with osteoporosis related fractures-results from a swedish survey. Working Paper Series in Economics and Finance, 512
49. OECD Health Data 2003-A comparative analysis of 30 countries. 2003 [cited; Available from: www.oecd.org/health/healthdata
50. World development indicators-relative prices and exchange rates. 2004 [cited 2004; Available from: http://siteresources.worldbank.org/ICPINT/ Resources/Table5_7.pdf
51. Kanis JA et al (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417-427
52. Zethraeus N Strom O, Borgstrom F (2006) What is the risk of institutionalization after hip fracture? Poster at ECCEO, Vienna
53. Jönsson B et al (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30-38
54. Kind P et al (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316(7133):736-741
55. Lundberg L et al (1999) Health state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Public Health 9(3):211-217
56. Kanis JA et al (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15(1):20-26
57. Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13(10):768-776
58. Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 323(7324):1300-1303
59. Översyn av samhällsekonomiska metoder och kalkylvärden på transportområdet-ASEK Review of cost benefit calculation. Methods and valuations in the transport sector. SIKA Rapport, 2002. 4
60. Kanis JA, Jönsson B (2002) Economic evaluation of interventions for osteoporosis. Osteoporos Int 13(10):765-767
61. Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health, W.C.o.M.a. Health, Editor. 2001:Geneva
62. Hart WM et al (2002) Análisis farmacoeconómico del tratamiento de la osteoporosis postmenopáusica con risedronato o alendronato. REEMO 11(3):97-104
63. Autier P, Belgian Hip Fracture Study Group et al (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Osteoporos Int 11(5):373-380
64. Ankjaer-Jensen A, Johnell O (1996) Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 6(4):265-275
65. Visentin P, Ciravegna R, Fabris F (1997) Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26(3):185-192
66. Andersen L et al (1995) Cost-effectiveness of alendronate for the prevention of osteoporotic fractures in Norwegian women. Statens Institutt for Folkhelse: Oslo
67. Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8(6):611-617
68. Kanis JA (2002) Epidemiology and costs of fractures in the UK: Background document for male osteoporosis model. Personal communication
69. Zethraeus N et al (2002) Costs and quality of life associated with osteoporosis related fractures-results from a Swedish survey. Working paper series in economics and finance, 512. Stockholm: Stockholm School of Economics
70. Puffer S et al (2004) Health care costs of women with symptomatic vertebral fractures. Bone 35(2):383-386
71. Local Government in Denmark. http://www.kl.dk/240830
72. 1. Stockholms stads budgetavräkning. Stadsledningskontorets redovisningsstab 2003 [cited]
73. Netten A, Rees T, Harrison G (2002) Unit costs of health and social care. Personal social services research unit: University of Kent. p. http://www.ukc.ac.uk/PSSRU/
74. System BSS Belgian Social Security System. [cited 2005-07-02]; Available from: http://www.riziv.be/insurer/fr/rate/pdf/2004/doctors/raad-20041001-fr.pdf
75. The danish ministry of health. Takstsystem 2001, 2000. ISBN 1395-2528
76. AMeli, L'Assurance Maladie en Ligne 2004 [cited; Available from: http://www.ameli.fr
77. EBM 2000 plus. 2004, Kassenärztliche Vereinigung Bayern
78. Medi 3 (internet reference,Norwegian private healthcare). 2005 [cited; Available from: http://www.medi3.no
79. Honorato J et al (2004) Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics 22(13):885-894
80. Curtis L, Netten A (2004) Unit costs of health and social care. Personal social services research unit: University of Kent. p. http://www.ukc.ac.uk/ PSSRU/
81. Osteoporosis in the European community: A call to action: an audit of policy developments since 1998, in international osteoporosis foundation. 2001
82. Priser för södra sjukvårdsregionen- Vårdtjänster per klinik. 2003 Universitetssjukhuset i Lund
83. Stevenson M, Jones ML, Nigris Ed. Assessment report: The clinical effectiveness and cost effectiveness of prevention and treatment of osteoporosis, http://www.nice.org. 2004 [cited
84. centre Belge d'Information Pharmacothérapeutique, the Belgian Pharmacotherapeutic Information Centre. 2005 [cited; Available from: http://www.cbip.be/GGR/MPG/MPG_NH.cfm#MP_2541
85. Lægemiddelkataloget (Denmark). 2004 [cited; Available from: http://www.lmk.dk
86. Vidal-pro (L'information de référence sur le médicament). 2004 [cited; Available from: http://www.vidalpro.net
87. Ministero della salute, Italy. 2004 [cited; Available from: http://www.ministerosalute.it/index.jsp
88. Felleskatalogen. 2004 [cited; Available from: http://www.felleskatalogen. no
89. Base de datos del medicamento. 2004 [cited; Available from: http://pfarmals.portalfarma.com:8080/farma/
90. FASS.se för Förskrivare. [cited 2004-05-06]; Available from: http://www.fass.se
91. British National Formulary 2004